66 research outputs found

    Chlamydia test-of-cure in pregnancy

    Get PDF
    Includes correction issued in August 2020 issue, page 554.Clinical Inquiries question: What is the optimal interval between treatment and test-of-cure (TOC) in pregnant women with Chlamydia trachomatis (CT)? Evidence-based answer: The optimal interval between treatment and TOC in pregnant women with CT is 3 to 4 weeks (strength of recommendation C: several small prospective and retrospective cohort studies; a high-quality nonsystematic review; and a consensus guideline). Testing before 3 weeks might give false-positive results, while waiting longer than 4 weeks might delay detecting new infections or result in treatment failure.Jessie Pettit, MD; Carol Howe, MD, MLS; Joshua Freeman, MDDr Freeman is Clinical Professor and Dr Pettit is Associate Professor in the Department of Family and Community Medicine at the University of Arizona in Tucson. Dr Howe is a librarian in the Health Sciences Library at the University of Arizona.Includes bibliographical reference

    The Ursinus Weekly, June 6, 1971

    Get PDF
    Harrison Salisbury to speak today • Dean Samuel Lucius Gandy is Baccalaureate speaker • Gold, Crane receive alumni senior award • Why Ursinus • 276 seniors graduate in ceremonies today • Editorial: Four years later • Looking ahead and looking back • A Letter from the President • Ursinus alumni welcomed home • Speakers selectedhttps://digitalcommons.ursinus.edu/weekly/1148/thumbnail.jp

    Fast acting allosteric phosphofructokinase inhibitors block trypanosome glycolysis and cure acute African trypanosomiasis in mice

    Get PDF
    The parasitic protist Trypanosoma brucei is the causative agent of Human African Trypanosomiasis, also known as sleeping sickness. The parasite enters the blood via the bite of the tsetse fly where it is wholly reliant on glycolysis for the production of ATP. Glycolytic enzymes have been regarded as challenging drug targets because of their highly conserved active sites and phosphorylated substrates. We describe the development of novel small molecule allosteric inhibitors of trypanosome phosphofructokinase (PFK) that block the glycolytic pathway resulting in very fast parasite kill times with no inhibition of human PFKs. The compounds cross the blood brain barrier and single day oral dosing cures parasitaemia in a stage 1 animal model of human African trypanosomiasis. This study demonstrates that it is possible to target glycolysis and additionally shows how differences in allosteric mechanisms may allow the development of species-specific inhibitors to tackle a range of proliferative or infectious diseases

    Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial

    Get PDF
    • …
    corecore